Literature DB >> 8859902

Adenosine A1 receptor-dopamine D1 receptor interaction in the rat limbic system: modulation of dopamine D1 receptor antagonist binding sites.

S Ferre1, P Popoli, B Tinner-Staines, K Fuxe.   

Abstract

Antagonistic interactions between adenosine A2a and dopamine D2 receptors and between adenosine A1 and dopamine D1 receptors have been previously found in the basal ganglia. Those interactions have been proposed to be key mechanisms of action responsible for the motor depressant effects of adenosine agonists and the motor activating effects of adenosine antagonists, like caffeine. By using quantitative receptor autoradiography, the selective adenosine A1 receptor agonist N6-cyclopentyladenosine was found to decrease the affinity of dopamine D1 receptors for the specific D1 antagonist [(125)I]SCH 23982 in both the nucleus accumbens and the medial prefrontal cortex of the rat brain. The present results suggest that dopamine neurotransmission, through an A1-D1 interaction, might also he involved in the behavioural effects of adenosine agonists and antagonists not related to motor activity, like the sedative-hypnogenic properties of adenosine analogues and the psychostimulant effects of caffeine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8859902     DOI: 10.1016/0304-3940(96)12577-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  18 in total

Review 1.  A possible mechanism for the dopamine-evoked synergistic disinhibition of thalamic neurons via the "direct" and "indirect" pathways in the basal ganglia.

Authors:  I G Sil'kis
Journal:  Neurosci Behav Physiol       Date:  2002 May-Jun

Review 2.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 3.  Implication of the purinergic system in alcohol use disorders.

Authors:  Liana Asatryan; Hyung W Nam; Moonnoh R Lee; Mahesh M Thakkar; M Saeed Dar; Daryl L Davies; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2011-01-11       Impact factor: 3.455

4.  Involvement of adenosine A1 and A2A receptors on guanosine-mediated anti-tremor effects in reserpinized mice.

Authors:  C M Massari; L C Constantino; N F Marques; L B Binder; M Valle-León; M López-Cano; V Fernández-Dueñas; F Ciruela; C I Tasca
Journal:  Purinergic Signal       Date:  2020-07-28       Impact factor: 3.765

Review 5.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

6.  Stimulation of adenosine receptors in the nucleus accumbens reverses the expression of cocaine sensitization and cross-sensitization to dopamine D2 receptors in rats.

Authors:  Benjamin D Hobson; Kathryn E Merritt; Ryan K Bachtell
Journal:  Neuropharmacology       Date:  2012-06-28       Impact factor: 5.250

7.  The time-course of ribavirin-provoked changes of basal and AMPH-induced motor activities in rats.

Authors:  Branka Janać; Vesna Pesić; Sanja Peković; Ljubisav Rakić; Mirjana Stojiljković
Journal:  Exp Brain Res       Date:  2005-05-10       Impact factor: 1.972

8.  Drosophila D1 dopamine receptor mediates caffeine-induced arousal.

Authors:  Rozi Andretic; Young-Cho Kim; Frederick S Jones; Kyung-An Han; Ralph J Greenspan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-11       Impact factor: 11.205

9.  Tuning and fine-tuning of synapses with adenosine.

Authors:  A M Sebastião; J A Ribeiro
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

10.  Adenosine A1 and dopamine d1 receptor regulation of AMPA receptor phosphorylation and cocaine-seeking behavior.

Authors:  Benjamin D Hobson; Casey E O'Neill; Sophia C Levis; Lisa M Monteggia; Rachael L Neve; David W Self; Ryan K Bachtell
Journal:  Neuropsychopharmacology       Date:  2013-04-18       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.